Photoimmunotherapy is an innovative cancer treatment that combines phototherapy with immunotherapy to selectively target and ...

Photoimmunotherapy with the M@P nanoplatform offers a novel approach, triggering cancer cell death and boosting immune ...

Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in phase 2 ...

Photoimmunotherapy is an innovative cancer treatment that combines phototherapy with immunotherapy to selectively target and ...

Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...

Harnessing immunogenic cell death (ICD)—an immunostimulatory form of cancer cell death in the tumor microenvironment—to help activate a patient’s immunity and trigger a tumor-specific immune ...

Developing low side-effect pyroptosis and ferroptosis inducers for cancer therapy, especially dual function inducers, is a ...

Neoantigen-targeting PCVs are highly immunogenic in high-risk clear cell RCC and can target key driver mutations and induce antitumor immunity.

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma. (HealthDay News) — Neoantigen-targeting personalized ...